Erythropoietin

Summary

Erythropoietin (EPO) is an endogenous glycoprotein hormone produced primarily by the kidneys in response to hypoxia. Recombinant human EPO (rhEPO) and its analogs are used clinically to treat anemia associated with chronic kidney disease, chemotherapy, HIV therapy, and surgery. It is also well-known as a performance-enhancing drug misused in endurance sports.

Mechanism of Action

Binds to the erythropoietin receptor (EPOR) on erythroid progenitor cells in the bone marrow, activating JAK2/STAT5 signaling pathways that promote proliferation, differentiation, and survival of red blood cell precursors, ultimately increasing circulating erythrocyte mass and hemoglobin levels.

Routes of Administration

Goals & Uses

• Treatment of anemia in chronic kidney diseaseHematology / NephrologyHigh
• Neuroprotection (investigational)Neurology / ResearchLow
• Treatment of chemotherapy-induced anemiaOncology / HematologyHigh
• Athletic performance enhancement (illicit)Sports / DopingModerate
• Reduction of allogeneic blood transfusions in surgerySurgery / Perioperative MedicineHigh
• Treatment of anemia in HIV-infected patients on zidovudineInfectious Disease / HematologyHigh

Contraindications

• Use to target hemoglobin above 11–12 g/dL in cancer patientsOncologyHigh
• Hypersensitivity to erythropoietin or excipientsAllergicHigh
• Thrombotic risk conditions (e.g., recent DVT, PE)HematologicalModerate
• Pure red cell aplasia (PRCA) due to prior EPO therapyImmunologicalHigh
• Uncontrolled hypertensionCardiovascularHigh

Adverse Effects

• HypertensionCardiovascularCommonHigh blood pressure
• Injection site reactionsLocalCommon
• HeadacheNeurologicCommonPain in the head or upper neck
• Thromboembolic events (DVT, PE, stroke, MI)Cardiovascular / HematologicalUncommon
• Tumor progression or recurrenceOncologicalUnknown
• Pure red cell aplasia (PRCA)Immunological / HematologicalRare

Drug Interactions

• Androgens (e.g., testosterone)Moderate
• Antihypertensive agentsModerate
• Iron supplementsLow
• Warfarin / anticoagulantsModerate

Population Constraints

• PregnancyReproductive SafetyRelative
• Patients with cardiovascular disease or recent strokeCardiovascularRelative
• Cancer patients not on chemotherapyOncologicalAbsolute
• Pediatric patients (neonates)AgeRelative

Regulatory Status

• European UnionApprovedApproved: Anemia due to chronic kidney disease, Anemia in adult cancer patients receiving chemotherapy, Anemia in adults with non-myeloid malignancies receiving chemotherapy (epoetin beta), Reduction of autologous blood transfusions in elective surgeryMultiple originator (Eprex, NeoRecormon) and biosimilar EPO products approved by EMA. Regular safety reviews have resulted in label updates restricting use.
• United StatesApprovedApproved: Anemia due to chronic kidney disease (dialysis and non-dialysis), Anemia due to zidovudine therapy in HIV-infected patients, Anemia due to myelosuppressive chemotherapy in cancer patients, Reduction of allogeneic red blood cell transfusions in elective surgeryApproved products include Epogen (epoetin alfa, Amgen) and Procrit (epoetin alfa, Janssen). ESA APPRISE Oncology REMS program required for cancer use. Biosimilars (e.g., Retacrit) also approved.
• United KingdomApprovedApproved: Anemia due to chronic kidney disease, Chemotherapy-induced anemia in adult cancer patients, Reduction of autologous blood transfusions in elective surgeryApproved products include Eprex (epoetin alfa) and biosimilars. MHRA follows EMA-derived guidance post-Brexit; same oncology restrictions apply.

Multiple recombinant EPO products are FDA- and EMA-approved; biosimilars are also approved. EPO is a prohibited substance on the World Anti-Doping Agency (WADA) banned list. Risk Evaluation and Mitigation Strategy (REMS) programs exist in the US (ESA APPRISE Oncology Program) due to tumor progression and cardiovascular risks in cancer patients.

Evidence & Sources

No sources recorded yet.